Cartilage

Nanochon closes $4M Series Seed Prime

Retrieved on: 
Lunedì, Maggio 6, 2024
Medical Devices, Surgery, Seniors, Clinical Trials, Other Health, Biotechnology, Physical Therapy, General Health, Consumer, Health, MD, Motion, University, Patient, Standard of care, Cartilage, Weight-bearing, Pharmaceutical industry

Nanochon, a Washington, DC-based orthopedic device biotech company has raised $4 million in its series seed prime fundraising round.

Key Points: 
  • Nanochon, a Washington, DC-based orthopedic device biotech company has raised $4 million in its series seed prime fundraising round.
  • The round was led by The University of Virginia Licensing and Ventures Group Seed Fund, with participation from Cultivate (MD), Alumni Venture Group, and Mountain State Capital, among others.
  • Nanochon intends to use the funds to initiate its first in human clinical trials in the US in 2024, deepen research and development efforts, expand the company’s patent profile and grow its team.
  • Nanochon has the potential to deliver more successful and longer-lasting recovery for patients than current standard of care.

Somite Therapeutics to Present at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASGCT)

Retrieved on: 
Mercoledì, Maggio 1, 2024
Doctor of Philosophy, AI, Cell, Poster, Diabetes, MD, Computational biology, B cell, PSC, Differentiable function, Obesity, SVP, Muscular dystrophy, Developmental biology, Gene, Society, MUSCULAR, Cartilage, Therapy, Translation, MIT, Pharmaceutical industry

BOSTON, May 1, 2024 /PRNewswire/ -- Somite Therapeutics, a tech-bio company leveraging big data and AI to introduce novel cell replacement therapies, today announced that the Company will present a poster at the upcoming American Society of Cell and Gene Therapy (ASGCT) Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

Key Points: 
  • [[To comply with academic institution guidelines, the founders' academic affiliations and roles are listed only at the end of the statement.]]
  • BOSTON, May 1, 2024 /PRNewswire/ -- Somite Therapeutics , a tech-bio company leveraging big data and AI to introduce novel cell replacement therapies, today announced that the Company will present a poster at the upcoming American Society of Cell and Gene Therapy (ASGCT) Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.
  • Founded in October 2023, Somite is building AI foundation models to produce human tissue at scale for cell therapies.
  • These therapies have the potential to treat a wide range of diseases that involve the loss or deficiency of cell populations, such as diabetes, obesity, and muscular dystrophies.

Space-Made Fibers and Novel Biotech Among Research Returning to Earth After Successful Space Station Mission

Retrieved on: 
Martedì, Aprile 30, 2024
Janus, SpaceX, Drug, SPACE, University, ISS, Seed, International Space Station, CRS, Research, Oklahoma State University–Stillwater, NASA, United States national laboratories, Commercial Resupply Services, Plant, B cell, Engineering, Therapy, Mathematics, Arthritis, Patient, ISS National Lab, ZBLAN, Health, Cartilage, Student, SpaceX Dragon, Growth, Choctaw Nation of Oklahoma, Communications satellite

KENNEDY SPACE CENTER, Fla., April 30, 2024 /PRNewswire/ -- Research on a novel vision loss therapy and space-manufactured optical fibers were among the nearly 565 pounds of science and technology payloads sponsored by the International Space Station (ISS) National Laboratory that splashed down off the Florida coast Tuesday morning as NASA concluded SpaceX's 30th Commercial Resupply Services (CRS) mission.

Key Points: 
  • Encapsulate leveraged the microgravity environment of the space station to validate an automated tumor-on-a-chip system that grows patient-derived cancer cells to test chemotherapy drugs.
  • Using powdered protein could significantly reduce the mass of materials sent to space for manufacturing, allowing increased production at a lower cost.
  • From mid-February to mid-March, the company manufactured a total of more than seven miles (11.9 km) of optical fiber on station.
  • These are just a few of the investigations returning to Earth in the SpaceX Dragon capsule on this mission.

FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office

Retrieved on: 
Giovedì, Aprile 11, 2024
Conditional sentence, Pain, Inflammation, Fibroblast, Health, Cartilage, Communication, Trial of the century, Form, Differentiable function, Joint, Therapy, I Am the Moon, Patent, Spine, Risk, Patient, Chondrocyte, Mutation, Regenerative medicine, Proteoglycan, Regeneration, Pharmaceutical industry

Cartilage is a vital connective tissue that provides cushioning, support, and flexibility to the joints including the spine.

Key Points: 
  • Cartilage is a vital connective tissue that provides cushioning, support, and flexibility to the joints including the spine.
  • “The awarding of this patent recognizes the novelty and utility of our method for cartilage regeneration using fibroblast and other cell types.
  • It strengthens our position in fibroblast cell therapy and regenerative medicine,” said Founder & Chief Executive Officer of FibroBiologics, Pete O’Heeron.
  • These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events.

Feinstein Institutes’ Daniel A. Grande Named President-Elect of the International Cartilage Regeneration & Joint Preservation Society (ICRS)

Retrieved on: 
Giovedì, Aprile 18, 2024
Health, Hospitals, Other Health, Other Science, General Health, Research, Science, Education, FDA, Rheumatology, EVS, Microsoft Exchange Server, Intervertebral disc, Regenerative medicine, Seminal vesicles, Cartilage, Doctor of Philosophy, B cell, Meniscus, ICRS, Patient, Tissue engineering, Molecular medicine, 3D bioprinting, Medical research, Microsoft Access, Multimedia, Regeneration, Stem cell, Credit, Journal, Medical device

The International Cartilage Regeneration & Joint Preservation Society (ICRS) has named Daniel A. Grande, PhD, assistant vice president of research services and professor of molecular medicine and orthopedic surgery at The Feinstein Institutes for Medical Research , its new President-Elect.

Key Points: 
  • The International Cartilage Regeneration & Joint Preservation Society (ICRS) has named Daniel A. Grande, PhD, assistant vice president of research services and professor of molecular medicine and orthopedic surgery at The Feinstein Institutes for Medical Research , its new President-Elect.
  • View the full release here: https://www.businesswire.com/news/home/20240418363701/en/
    Feinstein Institutes’ Dr. Daniel A. Grande has been named the new president-elect of International Cartilage Repair Society.
  • (Credit: Feinstein Institutes)
    Dr. Grande, renowned for his significant contributions to cartilage repair and regeneration, will lead the ICRS in its mission to advance science and education in preventing and treating cartilage injuries.
  • "I am honored and excited to serve as the President-Elect of the International Cartilage Regeneration & Joint Preservation Society.

ISS National Lab-Sponsored Research Could Produce Nanomaterials for Life-Saving Therapies and Precision Drug Delivery

Retrieved on: 
Giovedì, Aprile 25, 2024
Janus, SpaceX, SPACE, University, Cancer, ISS, Biomedical engineering, International Space Station, CRS, NASA, United States national laboratories, JBN, Commercial Resupply Services, Research, Nanoparticle, Engineering, Arthritis, Joint, Therapy, Science, Axiom Mission 2, DSM-IV codes, Messenger, Cartilage, Axiom Space, Temperature, Pharmaceutical industry

However, all this might soon change, thanks to a new investigation led by biomedical engineering researchers at the University of Connecticut.

Key Points: 
  • However, all this might soon change, thanks to a new investigation led by biomedical engineering researchers at the University of Connecticut.
  • Besides arthritis, these potentially life-saving nanomaterials could also treat cancer and neurological disorders.
  • Yupeng Chen, an associate professor for biomedical engineering at the university, is partnering with Eascra Biotech and Axiom Space to leverage the unique conditions available through the International Space Station (ISS) National Laboratory to produce DNA-inspired Janus base nanomaterials (JBNs).
  • The project, which was funded by the U.S. National Science Foundation, is still ongoing, but Chen says initial results from the research are very promising.

Woof Introduces Innovative Line of Wellness-Focused Pupsicle Pops & Soft Chews

Retrieved on: 
Mercoledì, Aprile 17, 2024
Relaxation, Magnesium, Pet, Taffy (candy), Health, Love, Mushroom, Parent, Joint, Allergen, Tryptophan, Nutrient, Dog, Cartilage, Immune system, Woof, Longevity, Pet industry

DENVER, April 17, 2024 /PRNewswire/ -- Woof, the award winning brand behind The Pupsicle, is proud to announce its newest (and tastiest) innovation yet - Wellness Pops. Reimagining the way pets access nutrition, Wellness Pops imbue essential nutrients into Pupsicle refill treats, delivering functional health benefits through long-lasting play that dogs love.

Key Points: 
  • DENVER, April 17, 2024 /PRNewswire/ -- Woof , the award winning brand behind The Pupsicle , is proud to announce its newest (and tastiest) innovation yet - Wellness Pops .
  • Reimagining the way pets access nutrition, Wellness Pops imbue essential nutrients into Pupsicle refill treats, delivering functional health benefits through long-lasting play that dogs love.
  • Woof's Wellness Line includes an array of products tailored to specific needs, like Joint Health, Allergy Support, Calming Support, and All-in-1 Nutrition.
  • Woof's new Daily Wellness line features a mix of Pupsicle Refill Pops and Soft Chew supplements, including:
    Joint Health Pops and Chews: Featuring Glucosamine, Green-Lipped Mussels, and Collagen, to support healthy bones, joints, and cartilage.

Somite Raises $5.3M As Five Leading Scientists Join Forces To Incorporate AI In Stem Cell Therapy

Retrieved on: 
Martedì, Aprile 16, 2024
Embryology, Diabetes, Cell, AI, OpenAI, Muscular dystrophy, Trust, Computational biology, Research, Artificial intelligence, B cell, Entrepreneurship, Differentiable function, Dermis, Developmental biology, Venture, Biology, Cartilage, Behavior, MIT

BOSTON and AUSTIN, Texas, April 16, 2024 /PRNewswire/ -- Somite, a venture-backed company aiming to become the OpenAI of stem cell biology, announces that it has raised $5.3M in pre-seed funding. The round was led by Israel's preeminent Venture fund TechAviv, and joined by renowned Austin-based VCs Next Coast Ventures, Trust Ventures and Texas Venture Partners as well as NY-based Lerer Hippeau and others. The funds will be used to continue development of Somite's proprietary AlphaStem AI platform, building Somite labs and bringing the first therapeutic asset to phase 1 clinical trials. 

Key Points: 
  • The funds will be used to continue development of Somite's proprietary AlphaStem AI platform, building Somite labs and bringing the first therapeutic asset to phase 1 clinical trials.
  • Founded in October 2023, Somite is building AI foundation models to produce human tissue at scale for cell therapies.
  • "The future of medicine lies at the intersection of AI and biology," says Micha Breakstone, CEO and Co-Founder of Somite.
  • They are committed to advancing their groundbreaking stem cell therapy technology and have the power to transform the lives of millions of people by leveraging AI to produce human tissue for cell therapies."

Hyalex Orthopaedics Appoints Thomas Vail, M.D., as Chief Medical Officer and Names Adam Gridley to Board of Directors

Retrieved on: 
Lunedì, Aprile 15, 2024
Education, Sale, University, Hip, Regenerative medicine, Abstract, Merz Pharma, Cartilage, Research, Trustee, ARM, Orthopedic surgery, IPO, Journal, Therapy, UCSF, Joint, Patient, Health, Biotechnology, Global health, Pharmaceutical industry

LEXINGTON, Mich., April 15, 2024 /PRNewswire/ -- Hyalex Orthopaedics, a privately held medical device company developing cartilage repair products based on the transformative HYALEX® materials platform, today announced the appointment of Thomas "Tad" Vail, M.D., as chief medical officer. Dr. Vail is internationally recognized as a specialist in total and partial joint replacement and surgical treatment of hip and knee conditions, having most recently served as the Michael and Antoinette Pappas endowed chair and James L. Young professor of orthopaedic surgery at the University of California, San Francisco (UCSF). Additionally, Hyalex announced the appointment of Adam Gridley, the chief executive officer of Allay Therapeutics, to the company's board of directors. These two appointments significantly augment the scientific and operational expertise of the Hyalex team at a time when the company is bringing its novel HYALEX Cartilage platform into first-in-human clinical trials.

Key Points: 
  • LEXINGTON, Mich., April 15, 2024 /PRNewswire/ -- Hyalex Orthopaedics, a privately held medical device company developing cartilage repair products based on the transformative HYALEX® materials platform, today announced the appointment of Thomas "Tad" Vail, M.D., as chief medical officer.
  • Additionally, Hyalex announced the appointment of Adam Gridley, the chief executive officer of Allay Therapeutics, to the company's board of directors.
  • "Hyalex is entering an exciting and transformational period for the company, as we advance our novel HYALEX Cartilage platform into the clinic for the first time.
  • "We look forward to the important contributions that both Tad and Adam will make to the success of the company."

Why you shouldn’t be afraid to start running after middle age

Retrieved on: 
Venerdì, Aprile 19, 2024
Knee, Atrophy, Pressure, MRI, Osteopenia, Exercise, Walking, Activity, Cell, Bone marrow, Chemical oxygen demand, Risk, Gamer, Research, Sarcopenia, Running, Rest, Joint, Volunteering, Life, Arthritis, Osteoporosis, Spine, Bed rest, Cartilage, Osteoarthritis, Skeleton, Dietary supplement

As someone who started marathon running in mid-life, I know how many aches and pains (and doubts) you can have if you take on the challenge to start running at an older age.

Key Points: 
  • As someone who started marathon running in mid-life, I know how many aches and pains (and doubts) you can have if you take on the challenge to start running at an older age.
  • Hobbling around my orthopaedic hospital after my first marathon actually led me to do research on runners.
  • The high-resolution MRI scans found most of the 115 middle-aged participants had abnormalities in their knees before starting marathon training.
  • But while osteoarthritis is more common after middle age, it may actually be a lack of activity that leads to osteoarthritis.
  • Reduced muscle use, whether it is through inactivity or sarcopenia or both, also reduces the production of anti-inflammatory myokines from the muscles.
  • These chemicals are released when we exercise, and help reduce joint swelling and calm irritated joint linings.
  • This effect is pronounced in runners because running uses some of the largest muscles in the body – such as the glutes, quadriceps and hamstrings.

Where to begin

  • If you want to start running, the main message is to ease into it to reduce the risk of injury.
  • One of the best ways to ease into running in mid-life is the NHS Couch to 5K running programme.
  • It’s a free guide that will help you gradually work up towards running 5km in just nine weeks.
  • If you’ve experienced any of these problems, you’ll want to be careful when exercising to avoid further damage.


Alister Hart receives funding from 3 charities: The Rosetrees Trust, Arthroplasty for Arthritis and The Maurice Hatter Foundation.